- title: Annual Meeting of the Society for Neuro-Oncology
  date: 2018-11-14
  location: New Orleans, Louisiana
  description: Presented a poster summarizing the most recent update on work the different effects of drug sensitivity and variability in drug in heterogeneous tumors on noninvasive imaging.
  resources:
  - title: Mathematical model of PDX tumor growth distinguishes differential sensitivity to EGFR inhibitor therapy and BBB effect
    url: https://drive.google.com/file/d/1WPOQnFKWKXoAre1vMIAEGbO8hPy8uoBu/view?usp=sharing

- title: Joint Physical Sciences-Oncology Network and Cancer Systems Biology Consortium Annual Investigators Meeting
  date: 2018-11-22
  location: National Institutes of Health, Bethesda, Maryland
  description: My poster featured some work I and an undergraduate assistant were beginning for investigating ways to assess drug blood-brain barrier pentetrability from noninvasive imaging data.
  resources:
  - title: Title
    url: https://drive.google.com/file/d/18lXNus3iWPjmsikxoXZDf22M8-i3Leh9/view?usp=sharing

- title: Joint Annual Meeting of the Society for Mathematical Biology and the Japanese Society for Mathematical Biology
  date: 2018-07-09
  location: University of Sydney, Sydney, Australia
  description: I organized a mini symposium on Data--Driven Mechanistic Cancer Models featuring speakers Trachette Jackson, Kit Curtius, Lee Curtin, Jill Gallaher, and myself. My talk (slides linked below) featured some work I and an undergraduate assistant were beginning for investigating ways to assess drug blood-brain barrier pentetrability from noninvasive imaging data.
  resources:
  - title: Glioblastoma invasiveness may predict response to therapies with high or low blood brain barrier penetrability
    url: https://drive.google.com/file/d/18lXNus3iWPjmsikxoXZDf22M8-i3Leh9/view?usp=sharing

- title: Annual Meeting of the Society for Neuro-Oncology
  date: 2017-11-16
  location: San Francisco, California
  description: I presented a poster summarizing....
  resources:
  - title: Change in extent of glioblastoma invasion following adjuvant temozolomide is driven by effect on non-enhancing tumor
    url: https://drive.google.com/file/d/12eCc6Sv3rkgVDa-bs6RMxHLlV4KnqFGb/view?usp=sharing
